Mia's Feed
Medical News & Research

Understanding Why Beneficiaries Leave Medicare Advantage Plans

Understanding Why Beneficiaries Leave Medicare Advantage Plans

Share this article

Recent research reveals that access to care and plan quality significantly influence why many seniors switch or leave Medicare Advantage plans. Discover the key factors driving these decisions and their implications for Medicare policy.

2 min read

Over half of older Americans currently receive their Medicare coverage through Medicare Advantage (MA) plans offered by private insurance companies. However, many choose to switch plans or revert to traditional Medicare during the annual Open Enrollment period each fall. Understanding the reasons behind these decisions has been challenging for researchers, partly due to limited data access, but recent studies provide new insights.

A study published in Health Affairs sheds light on the primary motivations for beneficiaries to change their Medicare coverage. The findings indicate that issues related to access to care and dissatisfaction with the quality of care are more influential than out-of-pocket costs in driving switches within MA plans. Specifically, enrollees who experience difficulties in obtaining necessary care or are unhappy with their care's perceived quality are more likely to change plans. Those in poor health are especially prone to leave MA for traditional Medicare, largely due to dissatisfaction with access.

Lead researcher Geoffrey Hoffman, Ph.D., an associate professor at the University of Michigan School of Nursing, explains that the study also highlights the role of plan quality ratings. Enrollees in plans with low star ratings or low benefit generosity tend to switch more frequently. Interestingly, the research suggests that those who stay in MA are often searching for better service, while those who switch to traditional Medicare are usually driven by unmet health needs and access issues.

The study utilized anonymous survey data linked with Medicare enrollment records, focusing on beneficiaries who had experienced at least eight months in their MA plan. It confirmed that dissatisfaction with access, care quality, and plan ratings significantly influences switching behavior.

Drivers of plan departure also have substantial implications for Medicare's financial management. When high-cost beneficiaries leave MA plans and return to traditional Medicare, costs for the government increase. Additionally, beneficiaries with serious health issues may face higher out-of-pocket costs after switching, especially in states where Medigap Supplemental plans—which help cover additional costs—are less accessible.

Overall, this research underscores the importance of plan quality and affordability, and highlights the ongoing need for transparent information to help beneficiaries make informed choices about their Medicare options.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

The Reality Behind 'New' Drugs: Patent Strategies and Rising Costs in Pharmaceuticals

Many so-called new drugs are minor modifications aimed at extending patents and increasing prices. Enhancing transparency and patent evaluation can promote genuine innovation and improve drug affordability.

Study Links Toxic 9/11 Dust Exposure to Blood Cancers and Genetic Changes

Research links toxic dust from the 9/11 WTC disaster to genetic mutations in blood cells, increasing the risk of leukemia among first responders. The study highlights inflammation's role and potential targets for preventive treatment.

Potential Impact of Caffeine on Blood Transfusion Effectiveness

New research reveals that caffeine consumption by blood donors can impair red blood cell quality, potentially reducing the effectiveness of blood transfusions. The study highlights the importance of personalized transfusion strategies considering lifestyle factors and genetic traits.

Breakthrough Drug Shows Promise in Treating Hormone-Related Hypertension

A groundbreaking clinical trial introduces Baxdrostat, a novel medication showing significant promise in treating hormone-driven high blood pressure, potentially offering a long-term cure for primary aldosteronism.